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Abstract
Tuberous sclerosis complex (TSC) is a tumor predisposition syndrome with
significant renal cystic and solid tumor disease. While the most common renal
tumor in TSC, the angiomyolipoma, exhibits a loss of heterozygosity associ-
ated with disease, we have discovered that the renal cystic epithelium is com-
posed of type A intercalated cells that have an intact Tsc gene that have been
induced to exhibit Tsc-mutant disease phenotype. This mechanism appears to
be different than that for ADPKD. The murine models described here closely
resemble the human disease and both appear to be mTORC1 inhibitor
responsive. The induction signaling driving cystogenesis may be mediated by
extracellular vesicle trafficking.
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Introduction
Tuberous sclerosis complex (TSC) is caused by mutations
in either the TSC1 or TSC2 genes and affects over one
million patients world-wide (Ewalt et al. 1998; Dabora
et al. 2001; Rakowski et al. 2006). Over 80% of young
patients and all postmortem samples (mean age 30 years
(Stillwell et al. 1987)) were found to have renal disease.
Renal cystic disease is detected by MRI in ~50% of TSC
patients, although the pathogenesis is not well studied.
Premature decline of glomerular filtration rate (GFR)
occurs in ~40% of patients with TSC (Bissler and Kings-
wood 2016) and can occur in the absence of overt
angiomyolipomata bleeding or interventions and is, at
least in part, due to renal cystic disease.
TSC renal cystic disease exhibits five distinct patterns
(Bissler 2018; Bissler and Kingswood 2018) and involves
the mechanistic target of rapamycin complex 1
(mTORC1) signaling pathway. The mTORC1 signaling
pathway integrates intra- and extracellular information to
regulate cellular metabolism, translation, growth, prolifer-
ation, autophagy, and survival and is critical for organo-
genesis and organ maintenance. The TSC proteins directly
regulate mTORC1 activity and influence downstream pro-
cesses, including renal development, homeostasis, and
malignancy. Although the TSC proteins play a pivotal role
in cell biology, how their regulation of the mTORC1
pathway is involved in cystogenesis is not known.
The etiology of another common TSC renal lesion,
angiomyolipomata, is thought to rely on a somatic muta-
tion mechanism that disables the functional copy of the
affected TSC locus leading to clonal proliferation of cells
lacking TSC-mediated regulation of the mTORC1 pathway
(Lam et al. 2017). There are multiple interactions between
mTORC1 signaling and candidate cystogenic mechanisms.
Investigation of both Tsc1- or Tsc2-associated renal cystic
disease mouse models directly (Onda et al. 1999; Zhou
et al. 2009; Armour et al. 2012) or indirectly (Chen et al.
2014) demonstrated that cystogenesis is attributable to
specific nephron segments, and all tubular segments have
been implicated in Tsc cyst formation (Traykova-Brauch
et al. 2008). The identification of the cell of origin for renal
cysts is complicated by the tubular epithelial capacity to
undergo dedifferentiation during repair/regeneration, and
restorative processes that recapitulate renal developmental
processes (Dziedzic et al. 2014). Interestingly, all mouse
model studies that examined both mTORC1 activity and
targeted cells exhibit a mismatch between exuberant cystic
phospho-S6 expression, and the much lower percentage of
cells exhibiting loss of Tsc expression (Onda et al. 1999;
Zhou et al. 2009; Armour et al. 2012).
Published mouse Tsc models are commonly reported to
be born with normal kidneys but cystogenesis progresses
with age. One such model has been reported to be associated
with a potassium excretion defect (Chen et al. 2014). Early
investigation revealed that the majority of renal cysts main-
tain their Tsc locus integrity (Onda et al. 1999; Wilson et al.
2006), as loss of heterozygosity was found in a striking
minority of cystic epithelial cells. This is similar to human
TSC renal cystic disease, where human cysts continue to
express tuberin and hamartin, and this contrasts with a very
different mechanism in the formation of angiomyolipomata,
which show an inactivating mutation and loss of Tsc gene
expression (Bonsib et al. 2016). Such a low percentage of loss
of heterozygosity is seen also in PKD1-associated autosomal
dominant polycystic kidney disease, suggesting that such cys-
tic disease may represent a unique disease mechanism (Bra-
sier and Henske 1997; Badenas et al. 2000).
To build on these initial studies of Tsc-associated renal
cystic disease in the mouse model system, we employed
two newly developed mouse Tsc-renal cystic disease mod-
els, one that disrupts the Tsc2 gene in renal principal
cells, and the other that disrupts the Tsc1 gene in renal
pericytes. These models suggest that, similar to renal
development, a tissue induction or reprogramming phe-
nomenon occurs such that cells with an intact Tsc gene
adopt Tsc-mutant cell phenotypes, defining a new and
distinct mechanism of disease from that reported for
angiomyolipomata development. These findings help
explain the discrepancies between disease tissue architec-
ture and persistence of TSC protein expression and
demonstrate that genetically normal, TSC-intact cells are
induced in large part to participate in cystogenesis.
Materials and Methods
Animal procedures
Ren-1c-Cre mice were generated in the laboratory of K.W.
Gross (Glenn et al. 2008). Floxed Tsc1 mice (stock
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#005680; (Kwiatkowski et al. 2002)) and Floxed Tsc2
mice (stock #027458) were obtained from The Jackson
Laboratory AqpCre mice and “Confetti” mice were also
obtained from The Jackson Laboratory. The “Confetti”
reporter uses the Brainbow2.1 cassette inserted into the
Rosa26 locus, where it is driven by the CAGG strong pro-
moter. The reporter system is activated by excision of a
floxed stop sequence by the Cre recombinase. The Brain-
bow reporter cassette contains two inverted repeats of flu-
orescent reporter genes: GFP paired with inverted YFP,
and RFP paired with inverted CFP. The loxP sites within
the construct are in direct and inverted orientations to
facilitate loss of the floxed stop module and expression of
one of the reporter pairs. The remaining reporter pair can
continue to “flip” into the active orientation for one of
the two inverted reporters while Cre activity remains pre-
sent, resulting in bi-colored cells, and will be locked into
one or the other orientation when Cre activity stops
(Snippert et al. 2010).
All animal research was done in adherence to the NIH
Guide for the Care and Use of Laboratory Animals. These
mice were crossed to generate offspring that were
heterozygous for the floxed allele, and were either
heterozygous or wild-type at the Cre allele. These
mice were then intercrossed to generate knockout mice
(Tsc1 fl/fl; Ren-1c-CreTg/+), wild-type mice (Tsc1+/+;
Ren-1c-Cre+/+) and controls for the floxed allele (Tsc1 fl/fl;
Ren-1c-Cre+/+), Cre allele (Tsc1+/+; Ren-1c-CreTg/+). A sim-
ilar strategy was used for the AqpCre lineages. Animals
were housed in a 12 h dark-light cycle according to proto-
cols approved by the University of Tennessee Health
Science Center Institutional Animal Care and Use Com-
mittee. For rapamycin injections, drug was dissolved in
vehicle (5.2% PEG 400/Tween 80) and injected at 3 mg/kg
three times per week starting at weaning (21 days of age).
Perfusions
Three clear plastic tubes were connected by three-way
stopcock to a peristaltic pump. The ends of two tubes
were placed in either 0.9% saline or 10% neutral buffered
formalin. A 30 ½ G needle was attached to the end of the
third tube. The formalin tube was filled to the stopcock
and the saline tube was allowed to flow from the needle
at a rate of 0.01 mL/sec. Prior to perfusion, mice were
anesthetized twice, first with isoflurane in a drop until
their heartbeat slowed to 1 beat per second, followed by
an intraperitoneal injection of 0.8 mL/20 g body weight
of Avertin. Once there was no reaction to painful stimuli
(e.g., toe pinch), the chest cavity was opened and the dia-
phragm cut. With the heart exposed, the apex of the left
ventrical was punctured with the 30 ½ G needle attached
to the perfusion liquid tubing and the aorta was cut. Mice
were perfused with 0.9% saline, followed by 10% neutral
buffered formalin for 10–12 min each. Dissected tissues
were stored in formalin overnight, then in 70% ethanol
(Pharmaco-Aaaper) until processing.
Histology and immunohistochemistry
staining
Tissues were processed with the following washes: 30 min
in 75% ethanol, 2 9 75 min in 95% ethanol, 3 9 1 h in
100% ethanol, 2 9 30–60 min in Citrosolv (Fisher Scien-
tific) and 2 9 1 h in Paraplast XTRA (Sigma-Aldrich),
with an additional final incubation overnight in Paraplast
XTRA under vacuum). Tissues were embedded into
blocks using Paraplast XTRA paraffin (Sigma-Aldrich) in
a Thermo Shandon Histocentre 3 paraffin embedding sta-
tion. For Immunohistochemistry, the kidneys from the
knockout mice (Tsc1 fl/fl; Ren-1c-CreTg/+) and wild-type
mice were prepared in 10% formalin fixed, paraffin
embedded. Tissue blocks were cut to 8 lm sections.
Immunohistochemical stains were carried out using the
The VECTASTAIN Elite ABC HRP Kit (Vector Labo-
ratories, Burlingame, CA) with DAB (3,3-diaminobenzi-
dine) as the chromogen (Vector Laboratories,
Burlingame, CA). The antibodies used are presented in
Table 1. All the sections were counterstained with Gill2
Hematoxylin (Fisher Scientific, Hampton, NH). In every
case, formalin-fixed tissue was subjected to heat-induced
antigen retrieval. Endogenous peroxidase activity was
blocked with 3% H2O2. Avidin/Biotin Blocking Kit (Vec-
tor Laboratories, Burlingame, CA) was used to block all
endogenous biotin, biotin receptors, and avidin-binding
sites present in tissues. For all immunohistochemical
studies, more that 95% of the slide had the reported pat-
tern of staining.
Immunofluorescence labeling
Single and double immunofluorescence labeling was per-
formed using established protocols (Xu et al. 2011;
Zahedi et al. 2013; Barone et al. 2018; Varasteh Kia et al.
2018). Briefly, animals were euthanized with an overdose
of pentobarbital sodium, and kidneys were perfused with
saline followed by 4% paraformaldehyde removed, cut in
tissue blocks, and fixed in 4% paraformaldehyde solution
overnight at 4°C. The tissue samples were preserved in
70% ethanol, paraffin embedded and 5-lm sections. For
staining, after rehydration and sodium citrate antigen
retrieval sections were incubated overnight at 4°C with
the primary antibodies (Table 1). Sections were then
washed in PBS and incubated with Alexa Fluor conju-
gated secondary antibodies (Invitrogen, Eugene, OR) for
one hour at room temperature. Sections were washed in
ª 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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PBS, dried and cover slips were applied using Vectashield
Mounting Medium (Vector Labs, Burlingame, CA).
Immunofluorescence microscopic analysis of tissue sec-
tions was performed on a Zeiss Axio Imager.M2 Micro-
scope. Images were acquired using Ziess Axiocam 506C
digital camera. Images were processed using Zeiss Zen
2012 software. For each figure, the settings for each panel
were identical. For all immunofluorescence studies, more
that 95% of the slide had the reported pattern of staining.
Multispectral imaging of kidney tissue
Kidney from Ren-1c-Cre, fl-Tsc1 or fl-Tsc2, Confetti were
excised immediately after euthanasia of the mice. One-
third part of both kidneys were cut into ~1 mm thick
sections. Individual sections were squashed to ~20 nm
thickness between two glass slides. The tissue was imaged
on an inverted Nikon Eclipse Ti fluorescent microscope
equipped with a Nuance FX multispectral camera. The
four fluorescent proteins encoded by Confetti were identi-
fied in the tissue based on reference spectra for each pro-
teins. The remaining kidney parts were fixed in
paraformaldehyde, embedded in OCT, and cut in a cry-
otome into 5-lm thick sections. The sections were ana-
lyzed by multispectral imaging as done for the fresh tissue
squashes.
Development of Tsc-mutant cell lines
We disrupted either the Tsc1 or Tsc2 genes in principal
cells using CRISPR/Cas9 genome editing as previously
described (Siroky et al. 2017a). A CRISPR plasmid with
constitutive green fluorescent protein (GFP) expression
and containing guide RNA sequences was constructed by
the Cincinnati Children’s Hospital Medical Center
(CCHMC) Transgenic Animal Genome Editing Core
Facility. The guide RNA sequences were selected using
algorithms in Benchling.com for on-target (Doench et al.
2014, 2016) and accounting for off-target (Hsu et al.
2013) sites. For both the Tsc1 and Tsc2 genes, exon 4 was
targeted. We used Lipofectamine 3000 (Thermo Fisher
Scientific) to transfect mIMCD-3 cells with these plas-
mids. At 2 days after transfection, single GFP-positive
cells were sorted into separate wells for expansion (FAC-
SAria II, BD Biosciences, San Jose, CA, located at the
CCHMC Research Flow Cytometry Core). After expan-
sion, extracted genomic DNA (GeneJET Genomic DNA
Purification Kit, catalog no. K0721, Thermo Fisher Scien-
tific) was used in a polymerase chain reaction (PCR; Phu-
sion Hot Start II DNA polymerase, catalog no. F549,
Thermo Fisher Scientific) to amplify the targeted region.
The resulting PCR products were screened for loss of the
AflII restriction site for Tsc1, and SphI restriction site for
Table 1. List of antibodies used in the study.
Antibody Dilution Source Catalog Number
Alexa Fluor Donkey anti-Goat IgG 1:200 Invitrogen; Eugene, OR A-11055
Alexa Fluor Goat anti-Mouse IgG 1:200 Invitrogen; Eugene, OR A-11001
Alexa Fluor Goat anti-rabbit IgG 1:200 Invitrogen; Eugene, OR A-11008
Anti-Hamartin 1:1000
1:1000
Cell Signaling Technology, Inc. Danvers, MA
ProteinTech Rabbit Polyclonal
4906
209988-I-AP
Anti-Na+/K+ATPase Dr. Jerry Lingrel, University of Cincinnati
Anti-phospho-P70S6Kinase (Thr389) 1:5000 Cell Signaling Technology, Inc. Danvers, MA 9205
Anti-Tuberin 1:2000 Cell Signaling Technology, Inc. Danvers, MA 3612
Anti-Tuberin ProteinTech Rabbit Polyclonal 20004-1-AP
Biotinylated Dolichos biflorus agglutinin (DBA) 1:300 Vector Laboratories, Burlingame, CA, USA RL-1032
Biotinylated Lotus Tetragonolobus Lection (LTL) 1:2,000 Vector Laboratories, Burlingame, CA, USA B-1325-2
Goat polyclonal Anti-PRR 1:50 Origene Technologies; Rockville, MD
HMB-45 1:40 Thermo Scientific, Waltham, MA MA5-16712
Mouse monoclonal Anti-AQP2 1:5,000 Dr. A. Blanchard, Paris-Descartes University
Mouse monoclonal Anti-H+ATPase 1:25 Dr. S. Holliday, University of Florida
Mouse monoclonal Anti-PCNA 1:100 Santa Cruz Biotechnologies; Dallas, TX SC-56
Phospho-S6 Ribosomal Protein 1:5,000 Cell Signaling Technology, Inc. Danvers, MA 2211
Rabbit polyclonal Anti-H+ATPase 1:100 Dr. M. Soleimani, University of Cincinnati
Rabbit polyclonal Anti-NBCe1 1:40 Dr. M. Soleimani, University of Cincinnati
Rabbit polyclonal Anti-NCC 1:60 Stressmarq Biosciences; Victoria, BC, Canada SPC-402
Rabbit polyclonal Anti-NHE3 1:60 Dr. Alicia McDonough, University of California at Los Angeles
Rabbit polyclonal Anti-Pendrin 1:15 Generated by Soleimani
S100 1:100 Abcam, Cambridge, MA ab52642
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Tsc2. PCR products of restriction site mutants were puri-
fied (GeneJet PCR Purification Kit, Thermo Fisher Scien-
tific) and sequenced (CCHMC DNA Sequencing and
Genotyping Core). For each gene, we selected clones that
had, in both alleles, a frame-shifting mutation that
resulted in an early stop codon.
Clonality assay
A modified clonality assay was used as previously described
(Nomura et al. 2004). DNA was extracted from cortical tis-
sues of wild-type and cyst walls of 11-week Aqp2CreTsc2
female-mice using commercial kit (PureLink, Thermo
Fisher Scientific). A total of 50 ng of DNA were digested
first with 1.7U of BfaI for 1-h followed by heat inactiva-
tion. This was followed by digestion with either 2U of
methyl-sensitive HpaII or 4U methyl-insensitive MspII as a
control in total of 15 lL reaction. Similar protocol fol-
lowed for undigested sample in which no HpaII or MspI
was added. A total of 2 lL of undigested, HpaII and MspI
digestion product were used to amplify the seventh CpG
island of mouse X-linked pgk-1 promoter with following
primers: CGCTGTTCTCCTCTTCCTCA (forward) and
GGACGCAGAAAA-GCAAACTC (reverse). PCR products
were separated in 1% agarose gel.
Extracellular vesicle isolation
Cells were serum starved for 24 hours. Serum-free media
were replaced and harvested after 24-hour incubation.
The conditioned media were centrifuged at 2000 g, 4°C
for 30 min to remove cells and debris. The supernatants
were transferred to new tubes with a half volume of total
Exosome Isolation reagent (Cat. # 4478359, Thermo fisher
Scientific). The tubes were mixed well and incubated
overnight at 4°C, and centrifuged at 10,000 g for 1 h at
4°C. The supernatant was aspirated and discarded, and
the pelleted extracellular vesicles were resuspended in
phosphate-buffered saline.
Human imaging studies
Following IRB approval, sequential de-identified patient
imaging was evaluated for cystic burden by cyst count.
Statistics
All statistical analyses were performed using the R pack-
age version 3.1.0 (Team RC 2018). Cox proportional haz-
ard models were performed using the Survival package
(version 2.38-3; (Therneau 2018; Therneau and Gramb-
sch 2000)). Animals that died due to sacrifice or disease-
related death were censored from the analyses.
Results
Mouse models of Tsc cystic kidney disease
The most severe forms of human TSC cystic disease include
polycystic variety associated with the contiguous gene syn-
drome (Brook-Carter et al. 1994; Jones et al. 1997) and
microcystic disease (Bissler 2018). There is a well-estab-
lished association between primary cilia defects and the
development of renal cystic disease. To create a mouse
model that would phenocopy these severe TSC renal dis-
eases, we targeted the primary cilia expressing renal collect-
ing duct principal cell. To achieve this, we disrupted the
floxed Tsc2 gene in the kidney using by aquaporin-2
(Aqp2) promoter to drive Cre-recombinase (Aqp2Cre)
expression. By crossing these Aqp2Cre transgenic mice with
floxed Tsc2 mice, we generated the Aqp2CreTsc2 mouse.
These mice have relatively normal kidneys at birth but
develop florid cystic disease by week 11 (Fig. 1A). At
11 weeks, mice that do not harbor the Aqp2Cre have kid-
neys that are 1 cm long, while mice that do express the
recombinase (Aqp2CreTsc2) have kidneys that are twice this
length and have visible cysts on the surface (Fig. 1A).
Coronal sections of the diseased kidney (Fig. 1B)
revealed a cortical cyst pattern. The cortical cysts were
not matched by medullary cysts over time, despite the
fact that the principal cell density increases along the col-
lecting duct into medulla. The Aqp2CreTsc2 mice had a
reduced median survival of 147 days and did not develop
angiomyolipomata.
We posited that there is a causal relationship between
angiomyolipomata and TSC renal cystic disease, so our sec-
ond model focused on cystic disease caused by disrupting
the Tsc axis in a putative cell of origin of angiomyolipo-
mata. Recent evidence suggests that angiomyolipomata
arise from a subpopulation of renal vascular pericytes (Sir-
oky et al. 2014); therefore, we used the Ren1cCre to disrupt
the floxed Tsc1 allele (Ren1cCreTsc1). Although Ren1cCre
recombinase is expressed in the renal pericyte compart-
ment, the animals most often develop cystic disease. The
disease appeared to be more commonly unilateral, without
a side preference. These mice also had a 25% reduction in
their litter sizes (P = 0.02 via Fisher’s Exact Test), suggest-
ing that bilateral disease compromised survival. The
affected kidney in these animals was larger than the grossly
unaffected contralateral kidney (Fig. 1C). Histologically the
affected kidney exhibited significant renal cyst epithelial cell
enlargement, some cystic epithelia were hyperplastic, and
occasional prominent nucleoli were identified (Fig. 1D).
These mice grew at a normal rate, with normal body weight
and no apparent gross developmental defects, but showed
lethality at a median of 85 days, essentially during
adolescence.
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Tsc genes in cystic epithelium remain intact
Because previous murine models of Tsc renal cystic dis-
ease do not show convincing “second hit” mechanism for
the Tsc renal disease (Onda et al. 1999; Wilson et al.
2006), and human TSC-associated cysts express hamartin
and tuberin (Bonsib et al. 2016), we wished to ascertain
the Tsc gene integrity in cystic epithelium in our models.
To assess if the cysts exhibited the loss of heterozygosity
as described in the angiomyolipomata, we used immuno-
histochemistry as well as a genetic analysis for Tsc2
recombination in the cysts from the Aqp2CreTsc2
mice. To validate the results, we used two different
commercially available antibodies with publicly available
validation for tuberin (ProteinTech 2018; Cell_Signal-
ing_Technology 2018) western blot analysis and a poly-
merase chain reaction assay to probe for recombination
by the maintenance of a LoxP2 site. We assayed one of
the antibodies by western blot to assure that we got
similar results to reported data (Cell Signaling, see
Table 1). To generate target cell lines, we used a parental
cell line from mouse inner medullary collecting ducts
(IMCD), and isogenic cell lines that were modified to
disrupt either Tsc1(T1H and T1J) or Tsc2 (T2H and T2J)
using CRISPR/CAS9 technology (Fig. 2A). The effect of
harmartin expression on tuberin expression has previ-
ously been reported (Benvenuto et al. 2000). We identi-
fied tuberin expression in cystic epithelium with both
antibodies. Furthermore, we found that the expression of
tuberin was not seen in the less common cell that
expressed aquaporin-2 (Fig. 2B). The cortical expression
and cysts was distinct from the expression in the medulla,
where again tuberin or aquaporin-2 expression were
mutually exclusive, but aquaporin-2 expressing cells were
much more numerous. To genetically assess Tsc2 gene
recombination, we used a PCR approach to see if the
loxP2 site was retained. The cystic epithelium demon-
strated the same size band comparing DNA from liver
Figure 1. Tsc renal cystic disease. (A) AqpCreTsc2 kidneys at 11 weeks with significant renal cystic disease. (B) Coronal sections of the kidney
in figure A. (C) Mouse kidneys from RenCreTsc1 mouse with unilateral cystic disease. These are on the same size scale as in A. (D) Coronal
section of kidney in figure C.
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and cyst wall epithelium (Fig. 2C). Sequencing these
bands demonstrated that they retain the sequence and
had not undergone Cre-mediated recombination
(Fig. 2D).
These results lead us to probe for recombination in the
cysts of the Ren1cCreTsc1 mice. The cystic disease in the
Ren1cCreTsc1 model has more numerous and smaller
cysts (Fig. 1C and D), so directly obtaining cystic tissue
would be more prone to contamination by DNA from
non-cystic cells. Instead, we probed for Ren1cCreTsc1
cystic Tsc1 deletion by breeding the Ren1cCreTsc1 onto
the “confetti” reporter background (Fig. 3A–D). We uti-
lized this technique to evaluate genetic status of the cysts
in Ren1cCreTsc1 affected kidneys. While we identified
clear fluorescence in arterioles, indicating Cre-mediated
recombination, we could not identify fluorescence in the
cystic epithelium in any of the slides screened. Thus, like
in the Aqp2CreTsc2 model, the genetic evidence corrobo-
rates the immunohistochemical evidence that Tsc genes
were intact in the cysts in these models.
Figure 2. Cystic epithelium express tuberin and have not undergone Cre mediated recombination. (A) Western blot of hamartin and tuberin
expression in IMCD cells and derived hamartin- (T1G and T1H) and tuberin-knockdown cells (T2H ad T2J). Knock-down of hamartin is known
to reduce tuberin expression (Barone et al. 2018). (B) Section of mutant kidney cortex and medulla. While the principal cells should express
aquaporin-2 and not tuberin, other cells that do not express aquaporin-2 should maintain tuberin expression. Cystic epithelium was restricted
to the cortex and continued to express tuberin (yellow arrows). At higher magnifications (63X) some aquaporin expressing cells were identified
(white arrows). The medullary cells, believed to be medullary collecting ducts, robustly expressed aquaporin-2. (C) Cystic epithelium exhibits a
PCR band that is the correct size for the non-recombined loxP2 site. (D) Sequencing these bands reveal that they contain the loxP2 site
indicating that they did not undergo Cre mediated recombination.
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Cellular composition of Tsc cystic epithelium
To characterize the renal cystic epithelial and gain insight
into the cystogenic pathways and/or mechanisms at play
in these models, we used both lectin and immunofluores-
cent staining. Multiple cystic epithelia histochemically
stained diffusely with Dolichos biflorus agglutinin (DBA),
which predominantly labels the collecting duct, while a
few cysts were not stained (Fig. 4A). To identify the
nephron segment(s) and the cell types comprising the cyst
epithelium, single and double immunofluorescence label-
ing experiments were performed using antibodies against
transporters, channels or molecules with specific nephron
segment distribution. We first probed for principal cells
labeling in renal collecting ducts of wild-type (left panel)
and Aqp2CreTsc2 mice (right panel) using anti-aquaporin-
2 (AQP-2) immunofluorescent staining (Fig. 4B). AQP-2
expression was present in non-cystic tubules but surpris-
ingly was absent in cyst epithelial cells in Aqp2CreTsc2 mice
(Fig. 4B, right panel). The labeling in wild-type kidney is
consistent with AQP-2 expression in principal cells
(Fig. 4B, left panel). A double immunofluorescence label-
ing with AQP-2 (green) and H+-ATPase (red), a marker of
intercalated cells, in a normal mouse kidney shows multiple
principal cells (AQP-2 positive) interspersed with interca-
lated cells (H+-ATPase positive) in wild-type cortical col-
lecting ducts (Fig. 4C). Using AQP-2 and H+-ATPase
double immunofluorescence staining in the Aqp2CreTsc2
kidney revealed an age-dependent change. Figure 4D
demonstrates double immunofluorescent labeling with
AQP-2 (green) and H+-ATPase B subunit (red) in kidneys
of 5 weeks (left panel) and 11 weeks old (right panel)
Aqp2CreTsc2 mice. As shown, 5 weeks old Aqp2CreTsc2
mice exhibit early signs of cyst development in their kid-
neys (depicted with the letter “C”). Several principal cells
and numerous intercalated cells are present in cyst epithe-
lium as verified by the expression of AQP-2 (green) and
H+-ATPase (red), respectively, in distinct cells. Interest-
ingly, the H+-ATPase-positive cells (white arrows) are more
abundant compared to AQP-2 positive cells (yellow
arrows) in cyst epithelium. Kidneys of 11 weeks old Aqp2-
CreTsc2 mice (Fig. 4D, right panel) show more frequent
and larger cysts in the cortex and display robust and almost
uniform expression of H+-ATPase along the apical mem-
brane of cyst epithelium. There are very few AQP-2 positive
cells in cyst epithelia in 11 weeks old Aqp2CreTsc2 mice
A B
C D
Figure 3. The Tsc1 gene has not undergone recombination in the cystic epithelium of the Ren1cCreTsc1 model. (A) Brightfield of Ren-1c-
CreTsc1 kidney arteriole, denoted by “v”, and cysts, denoted by “c”. (B) Fluorescence of the same tissue in panel A demonstrating vascular
pericyte derived fluorescence, while cysts are devoid of signal. (C) Brightfield of arteriole and cysts. (D) Fluorescence of tissue in C with only
vessel fluorescing.
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Figure 4. Cyst epithelial phenotypes in AqpCreTsc2 mice. (A) DBA staining in cyst epithelia in AqpCreTsc2 (Tsc-2 KO) mice. (B) Expression of
AQP-2 in kidneys of WT (left) and AqpCreTsc2 (Tsc-2 KO) mice (right). (C) Double immunofluorescence labeling with AQP-2 (green) and
H+-ATPase (red) antibodies in normal kidney (merged image). (D) Double immunofluorescent labeling with AQP-2 (green) and H+-ATPase (red)
in kidneys of 5 weeks (left panel) and 11 weeks old (right panel) AqpCreTsc2 mice (merged image). (E) Expression of prorenin receptor (PRR) in
kidneys of AqpCreTsc2 mouse. Left panel: normal kidney; Middle panel: 5 weeks old AqpCreTsc2 mice. Right panel: 11 weeks old AqpCreTsc2
mice. (F) Double immunofluorescent labeling with NBC-e1 (right panel) and H+-ATPase B subunit (left panel) in kidneys of 11 weeks old
AqpCreTsc2 mice. (G) Cyst double labeling with H+-ATPase (green arrow) and AE-1 (red arrow), additional evidence that cystic epithelium
consists of type A intercalated cells. (H) Double immunofluorescence labeling with H+-ATPase and AQP-2 in kidneys of Pkd1 mouse (merged
image). (I) PCR products of female mouse pgk-1 promoter region on the X chromosome, for undigested sample, U, methyl-dependent HpaII
digested, H, and methyl-independent MspI digested samples from WT and AqpCreTsc2 mice. Cystic cell DNA is not clonal as band intensity is
diminished by > 25% when input DNA is pre-digested with HpaII. C: cyst, G: Glomerulus
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(Fig. 4D, right panel). These changes are consistent with
the proliferation of A-intercalated cells and gradual disap-
pearance of principal cells in cyst epithelium.
We were intrigued by the H+-ATPase in the interca-
lated cells because in the kidney, the prorenin receptor
(PRR) co-localizes with H+-ATPase in intercalated cells
and functions as a receptor for renin. Pro-renin, a critical
chaperone for the assembly of H+-ATPase subunits, regu-
lates cell proliferation via the mitogen activated protein
kinases ERK1/2 cascade and is a crucial component of
Wnt pathways (Kaneshiro et al. 2006; Cao and Feng
2013; Seva Pessoa et al. 2013; Sihn et al. 2013; Danser
2015; Ramkumar and Kohan 2016a,b; Peters 2017). There
is robust and uniform PRR expression on the apical
membrane of cyst epithelium in 11 weeks old Aqp2-
CreTsc2 mice (Fig. 4E, right panel) and parallels the H+-
ATPase expression pattern, as does the PRR expression in
the 5-week old Aqp2CreTsc2 mice (Fig. 4E, middle panel).
PRR expression in control animals is shown for compar-
ison (Fig. 4E, left panel).
To determine whether other nephron segments or tubu-
lar cells contribute to cyst epithelium, we performed dou-
ble labeling with the Na+:HCO3
 cotransporter NBC-e1
(red fluorescence), which primarily labels the basolateral
membrane of proximal tubule and thick ascending limb of
Henle (TALH), and H+-ATPase (green fluorescence),
which is strongly expressed in intercalated cells. NBC-e1
(Fig. 4F, right panel) was detected in normal, non-cystic
nephron segments, but was completely absent in cyst
epithelial cells in adult Aqp2CreTsc2 mice. The H+-ATPase
showed a very strong and uniform labeling in cyst epithe-
lial cells (Fig. 4F, left panel). The Na-Cl cotransporter
NCC, a marker of distal convoluted tubule, and pendrin, a
marker of B-intercalated cells, did not show any labeling
in cyst epithelia (Data no shown). Additional staining for
the sodium-hydrogen exchanger-3, a marker of proximal
tubule and thick ascending limb of Henle, failed to iden-
tify this transporter in the cystic epithelium (Data not
shown). The Na+-K+ ATPase showed normal expression
in non-cystic nephrons but displayed minimal basolateral
labeling in cyst epithelial cells (Data not shown). Cystic
epithelium does express type A intercalated cell localiza-
tion of H+-ATPase on the apical surface and AE-1 on the
basolateral surface (Fig. 4G).
Because we identified a new cystogenic mechanism, we
wished to compare Tsc renal cystic disease to Pkd1 renal
disease. Kidney sections from a Pkd1-mutant mouse (gen-
erated using a PAX8 cre mouse and a generous gift from
Dr. Stephen Somlo) were examined for the expression of
H+-ATPase and AQP-2. Double immunofluorescence
studies demonstrate that in Pkd1-mutant mice, cysts orig-
inating from the cortical collecting duct contain both
principal cells and intercalated cells (Fig. 4H).
We used female mice and X-chromosome inactivation
to assess if type A intercalated cells in cystic epithelia
results from expansion of single cell (i.e., monoclonal) or
multiple cells (polyclonal). Figure 4I shows a greater than
25% reduction in methylated-pgk1 locus on the X chro-
mosome in cortical tissues of wild type and cystic epithe-
lia of Aqp2CreTsc2 female mice, more strongly supporting
a polyclonal nature of the cystic epithelium.
The absence of labeling with AQP-2, pendrin, NBC-e1,
NCC or NHE-3 antibodies in renal cystic epithelium of
Tsc2-specific knockout mice indicated that the cysts were
not comprised of the targeted principal cells, nor the
B-intercalated cells, proximal tubule cells, thick ascending
limb of Henle cells or distal convoluted tubule cells. The
H+-ATPase apical location correlated very well with the
cyst fluid pH that ranged from 5 to 5.6, and was most
compatible with the cystic epithelium exhibiting an
A-intercalated cell phenotype. This cell of origin is also
important as the intercalated cells do not express a pri-
mary cilia, and the cysts in out model also fail to express
significant cilia (Fig. 5).
Because of the novel cystogenic process in the Aqp2-
CreTsc2 model, we conducted similar studies in the
Ren1cCreTsc1 model. As with the Aqp2CreTsc2 mouse
model, the DBA staining was detected in most but not all
cysts in the Ren1cCreTsc1 model (Fig. 6A). Similar to
Aqp2CreTsc2 mice, the Ren1cCreTsc1 mice did not show
any expression of AQP-2 on the apical membrane of cyst
epithelia (Fig. 6B, right panel). The expression of AQP-2
in cortical collecting duct in a normal kidney is shown
for comparison (Fig. 6B, left panel). The double labeling
with NBC-e1 and H+-ATPase revealed a strong and uni-
form expression of H+-ATPase on the apical membrane
of cyst epithelia but did not demonstrate any labeling
with NBC-e1, a marker of proximal tubule and thick
ascending limb of Henle cells (Fig. 6C, right panel). The
expression of NBC-e1 in normal kidney (Fig. 6C, left
panel) and in non-cystic kidney tubules in RenCreTsc1 is
shown (Fig. 6C, right panel). The cystic epithelia showed
a strong and uniform expression of PRR on their apical
membrane (Fig. 6D). The double labeling with Na+-K+
ATPase and NBC-e1 indicates basolateral expression of
Na+-K+-ATPase in multiple nephron segments in normal
kidney (Fig. 6E, first and third panels). In Ren1cCreTsc1
mice, the Na+-K+-ATPase exhibits strong basolateral
expression in non-cystic tubules and mild expression in
cystic epithelia (Fig. 6E, fourth panel). The basolateral
Na+:HCO3
 cotransporter NBC-e1 shows no expression
in cystic epithelia but shows normal expression in non-
cystic epithelia (Fig. 6E, second panel). There was no
labeling with NCC, pendrin, or NHE-3 antibodies in
renal cysts, indicating the lack of B-intercalated cells,
principal cells, distal convoluted tubule cells, proximal
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tubule cells or thick ascending limb of Henle cells in cyst
epithelium adult Ren1cCreTsc1 mice.
To better establish the role of intercalated cells in cyst
epithelia proliferation in these Tsc knockout mice, we
performed double labeling with H+-ATPase and prolifer-
ating cell nuclear antigen (PCNA) in kidneys of Aqp2-
CreTsc2 and Ren1cCreTsc1 mice (Fig. 6F). Similar staining
was performed on kidneys from Pkd1 mice (Fig. 6F,
fourth panel). For comparison, PCNA labeling in wild-
type mice is shown (Fig. 6F, first panel).
As observed in multiple high magnification images,
wild-type mice showed very few PCNA-positive cells per
each field (Fig. 6F, first panel). However, the H+-ATPase-
expressing epithelial cells lining the cysts in Aqp2CreTsc2
mice showed numerous PCNA-positive cells (Fig. 6F, sec-
ond panel). Similarly, the cyst epithelium in Ren1cCreTsc1
mice showed many H+-ATPase expressing cells that also
displayed positive staining for PCNA (Fig. 6F, third
panel), a pattern very similar to Aqp2CreTsc2 mice. The
cells lining the cysts in Pkd1 mice showed a relative
increase in the number of PCNA-positive cells in cyst
epithelium as compared to wild-type mice (Fig. 6F,
fourth panel). However, the number of PCNA-positive
cells in Pkd1 mice was significantly less than that in Aqp2-
CreTsc2 or Ren1cCreTsc1 mice. Furthermore, only a
minority of PCNA-expressing cells showed co-labeling
with H+-ATPase (Fig. 6F, fourth panel).
Our results consistently indicate that A-intercalated
cells with an unrecombined Tsc gene are induced or
reprogrammed to form cysts in both Aqp2CreTsc2 or
Ren1cCreTsc1 models. Basically, the loss of heterozygosity
in the small number of cells would be combined with a
gain of function mechanism that affects the surrounding
genetically unrecombined cells and tissue. The significant
difference in A-intercalated cell expansion in Tsc knock-
out mice versus Pkd1 mice (results above) highlights the
difference in the role of A-intercalated cells in these two
kidney cystic models.
mTORC1 inhibition response of genetically
normal cystic cells
The examination of these two very different murine mod-
els of real cystic disease suggest the presence of a com-
mon mechanism involving the adoption of a Tsc-mutant
phenotype in genetically normal cells that is induced by
the loss of Tsc function in a small number of adjacent
cells. These observations have important implications as
far as mechanism of disease and possible response to
mTORC1 inhibitors are concerned. Such inhibitors are
effective and are approved for the treatment of TSC-asso-
ciated renal angiomyolipomata (Bissler et al. 2008, 2013),
subependymal giant cell astrocytomas (Franz 2013), and
lymphangioleiomyomatosis (Bissler et al. 2008;
A B
C D
Figure 5. AqpCreTsc2 cystic epithelium exhibit much fewer primary cilia than adjacent tubules. (A) Immunofluorescence of acetylated tubulin
(yellow arrow) easily identify primary cilia in a medullary collecting duct. (B-D) Cystic epithelium exhibit a significant suppression of primary cilia
(white arrow) but does exhibit occasional cilia (yellow arrow).
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McCormack et al. 2011) and possibly small cysts in
humans (Siroky et al. 2017b). However, unlike the
angiomyolipomata in human, these murine models of
cystic renal disease involve non-mutant epithelium (Franz
et al. 2018).
To determine if mTORC1 activation was involved in this
new cystogenic mechanism, we first examined the
phospho-S6 staining in the Aqp2CreTsc2 cystic tissue.
There was a uniform increase in phospho-S6 staining of the
cystic epithelium (Fig. 7A). There was also a significant
increase staining for phospho-S6 in the Ren1cCreTsc1 cystic
epithelium (Fig. 7B). These results support the involve-
ment of the mTORC1 pathway in this novel mechanism of
cystogenesis, even though the Tsc genes are intact. To test
Figure 6. Cyst epithelial phenotypes in Ren1cCreTsc1 mice. (A) DBA staining in cyst epithelia in Ren-1c- CreTsc1 (Tsc-1 KO) mice. (B)
Expression of AQP-2 in kidneys of WT and Ren1cCreTsc1 mice. (C) Double immunofluorescence labeling (merged image) with H+-ATPase
(green) and NBC-e1 (red) antibodies in normal kidney (left) and adult Ren1cCreTsc1 mice (right). (D) Expression of PRR in kidneys of
Ren1cCreTsc1 mice. (E) Double immunofluorescence labeling with Na+-K+ ATPase (green) and NBC-e1 (red) in normal kidney (first and third
panels) and Ren1cCreTsc mice (second and fourth panels). (F) Double immunofluorescence labeling with H+-ATPase (red) and PCNA
(Proliferating Cell Nuclear Antigen) antibodies (merged image) in kidneys WT, AqpCreTsc2, RenCreTsc1, and Pkd1 mice.
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whether inhibiting the mTORC1 axis could be therapeutic,
we treated animals from both models with rapamycin and
used survival as a readout of effect. Administration of rapa-
mycin for the Aqp2CreTsc2 and the Ren1cCreTsc1 signifi-
cantly prolonged the animal survival (Fig. 7C and D).
Implications for human disease
The polycystic and the microcystic kidney variety of TSC
lead to loss of renal function by adolescence or young
adulthood. These forms of TSC renal cystic disease are in
the most need of therapeutic intervention. Given the
unexpected results reported here, we wished to determine
if human disease exhibited a similar pathology and
response to mTORC1 inhibition. To test the staining
characteristics of human TSC renal cystic disease associ-
ated tissue, we used a nephrectomy specimen for the
polycystic kidney disease phenotype (Fig. 8A). Similar to
the mouse models, the human TSC cystic apical epithe-
lium revealed H+-ATPase staining (Fig. 8B) and demon-
strated findings again consistent with cystogenic
participation of A-intercalated cells. A similar finding was
also revealed in the staining of the microcystic disease
biopsy (Fig. 8C).
While the A-intercalated cells appear to be involved in
human TSC renal cystic disease, therapeutic response to
mTORC1 inhibition is not clear. Although one publica-
tion suggested a possible response of mild TSC cortical
cystic disease to mTORC1 inhibitor therapy (Siroky et al.
2017b), it is not clear that mTORC1 inhibition is useful
for severe forms of TSC renal cystic disease. We examined
patients with the focal and cortical cystic variants of TSC
(Bissler and Kingswood 2018) who were on an mTORC1
inhibitor clinically and found that they also respond to
mTORC1 inhibitors by reducing their cystic burden
(Fig. 8 D and E). Five TSC patients were identified that
were placed on an mTORC1 inhibitor with either focal or
cortical cystic kidney disease for at least 1 year. Total
renal cystic count of the cysts were performed prior to
therapy and after at least 1 year, and a significant reduc-
tion (P < 0.025 ratio paired t-test) of cystic burden was
identified (Fig. 8F).
Possible role of extracellular vesicles in
disease phenotype induction
To begin to explore possible mechanisms for the pheno-
typic induction that we described in this manuscript, we
tested the probability that extracellular vesicles may be
involved. This exploration was based on several reasons.
First, such extracellular vesicles are a prominent compo-
nent of renal pathophysiology (Pomatto et al. 2017), and
their release is stimulated by ER stress (Kanemoto et al.
2016) such as that which occurs in cells with a disrupted
TSC (Siroky et al. 2012). Second, extracellular vesicle
release as well as fusion are known to be increased in an
acidic extracellular environment (Parolini et al. 2009;
Maas et al. 2017), and the cyst fluid in the Aqp2CreTsc2
Figure 7. mTORC1 involved in cystic disease. (A) AqpCreTsc2 cysts stain robustly for phospho-S6 (bar is 50 lm). (B) RenCreTsc1 cysts also stain
robustly for phospho-S6 (bar is 1000 lm). (C) mTORC1 inhibition significantly prolongs AqpCreTsc2 survival compared to sham treated
(P = 0.0293) (n = 5 mice each group). (D) mTORC1 inhibition also significantly prolongs RenCreTsc1 survival compared to sham-treated animals
(P < 0.0001) (n = 10 mice each group).
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model has a pH = 5.0, likely as a result of increased H+-
ATPase expression and activity in the luminal aspect of
the cyst. Lastly, increased release of extracellular vesicles
has also been shown to occur in states of hypoxia or
conditions of increased HIF1a production (King et al.
2012), such as that seen with increased mTORC1 activity
driving increased HIF1a (Dodd et al. 2015). In early
cysts we were able to identify extracellular vesicles in the
cyst lumen (Fig. 9A), and could also detect either vesicle
shedding or fusion with the apical epithelial cell
(Fig. 9B). To test if these vesicles could mediate the
increased mTORC1 activity, we developed a cell culture
experiment using IMCD conditioned media by itself, or
isolated extracellular vesicles from either one or three
milliliters of conditioned media in experiments using
intercalated cells (M1 cortical collecting duct cell line) as
a target (Fig. 9C). This cell line does not express primary
cilia, and morphologically this cell is most compatible
with an intercalated cell line (Stoos et al. 1991). We used
western blot analysis of phospho-S6 as a read out of
mTORC1 activity.
We used a parental IMCD cells, and isogenic cell lines
that were modified to disrupt either Tsc1 or Tsc2 using
CRISPR/CAS9 technology (Fig. 2A). To examine the pos-
sible transfer mTORC1 pathway activity from the IMCD
cells to the intercalated cells by extracellular vesicles, we
determined the phosphorylation of S6 kinase of M1 cell
lysates after 24 h of exposure to isolated extracellular vesi-
cles (Fig. 9D). Comparing the phospho-S6 band to the S6
band, there is a significant increase in the phospho-S6/S6
ratio with the higher dose of extracellular vesicles derived
from the Tsc2-deficient IMCD cells (Fig. 9D).
Discussion
We report a new cellular cross-talk mechanism resulting
in tuberous sclerosis renal cystogenesis. A fundamental
feature of this mechanism involves a small population of
Tsc-mutant renal principal epithelial cells or pericytes that
induce or reprogram genetically normal A-intercalated
cells to upregulate their mTORC1 activity, proliferate, and
form renal cysts (Fig. 10). Similar microenvironmental
A B C
D E F
Figure 8. Human Polycystic variety of TSC renal Disease. (A) Human polycystic kidney variety of TSC renal disease at nephrectomy. (B) Cyst
epithelium from kidney in panel A exhibiting apical staining with H+-ATPase antibody (bar is 100 lm). (C) Biopsy specimen from patient with
TSC-related microcystic disease exhibiting apical staining with H+-ATPase antibody (bar is 100 lm). (D) MRI imaging (T2 fast spin echo with fat
suppression) from patients with TSC cystic disease (white lesions in solitary left kidney) before mTORC1 inhibitor therapy, (E) Patient in panel
“D” after one year on drug. (F) Analysis of total kidney cyst count from five patients with cortical cystic disease and focal cystic disease before
and after mTORC1 therapy.
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Figure 9. Inner medullary collecting duct (principal) cells produce extracellular vesicle that induce intercalated cell mTORC1 signaling. (A)
Microscopic cyst containing extracellular vesicles in lumen (arrow). (B) Extracellular vesicles either budding from or fusing with apical epithelial
cell surface (arrow). (C) Diagram of experimental design. Intercalated cells were exposed to principal cell derived conditioned media or isolated
extracellular vesicles. (D) Western blot of phospho-S6 and S6 in cultured intercalated cells. To calibrate experiment, intercalated cells were
exposed to FBS or serum starvation (FBS-), or isolated extracellular vesicles from 1 mL (ECV-1) or 3 mL (EVC-3) of the corresponding
conditioned media. ** Student t test P < 0.01.IMCD cells, derived hamartin- (T1G and T1H) and tuberin-knockdown cells (T2H ad T2J). Bar
diagram shows optical density of three independent experiments (Mean  SEM).
Figure 10. Model of TSC Cystogenesis. Cortical collecting duct contains three types of intercalated cells (see color key) and principal cells that
express cilia (blue). Stimulation initiated from either the mutant principal cells or the mutant vascular pericytes (arrows), drive the type A
intercalated cells to adopt a mutant phenotype and proliferate (dashed arrows).
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effects that increase malignant potential have implicated
extracellular vesicles (Zomer et al. 2015). Extracellular
vesicles derived from Tsc1-null cells transform the pheno-
type of neighboring wild-type cells in vivo such that the
wild-type cells became functionally similar to Tsc1-null
cells (Patel et al. 2016), a phenomenon sometimes termed
“phenotypic spreading”. Such extracellular vesicles have
been demonstrated to affect renal tubular changes in a
von Hippel Lindau zebrafish model (van Rooijen et al.
2018). This extracellular vesicle initiating event has appeal
because as the cyst develops, the tubular lumen increases
in diameter and exponentially reduces the flow, thus
increases the time for the extracellular vesicles to interact
with intercalated cells. As the cysts enlarge, they detach
from the tubule (Grantham et al. 1987), potentially
entrapping the extracellular vesicles in the closed cystic
space. The intercalated cells with the increased mTORC1
activity likely also participate in the process both in shed-
ding and uptake of the vesicles. This effect also may be
mediated through a cellular reprogramming mechanism
that induces a sustained change in cellular activity in a
paracrine-like (principal or pericyte to intercalated cell)
or autocrine-like fashion (intercalated to intercalated
cells) (Quesenberry et al. 2015). Such a programming
effect has been shown in vitro using cells derived from a
TSC patient angiofibroma (Julian and Stanford 2017).
Our mouse models and human samples demonstrate a
significantly increased preponderance of H+-ATPase posi-
tive A-intercalated cells and disappearance of principal
and B-intercalated cells in the cystic epithelium (Figs. 4
and 6). The vacuolar H+-ATPase is ubiquitously expressed
in the membranes of intracellular organelles, including
lysosomes, where it plays a crucial role in their acidifica-
tion. The H+-ATPase is also found in the plasma mem-
branes of certain specialized cell types, including kidney
A-intercalated cells, epididymis, osteoclasts, and certain
tumor cells (Blake-Palmer and Karet 2009; Brown et al.
2009; Gennari 2011; Lee 2012; Breton and Brown 2013;
Crambert 2014). H+-ATPase plays an important role in
stimulating chloride secretion via apical chloride channels
in the collecting duct (Fernandez et al. 1997). These
results support the presence of a mechanism that drives
the progressive expansion of A-intercalated cells and the
disappearance of principal cells similar to what is
described for the differentiation of ionocytes and ker-
atinocyte maintenance in zebra fish embryos (Janicke
et al. 2007).
Communication between H+-ATPase and mTORC1 is
implicated in reciprocal amplification of their functions.
A significant role for H+-ATPase in mTORC1 regulation
and translocation to the lysosomal membrane has been
demonstrated in several conditions (Zoncu et al. 2011).
The H+-ATPase undergoes amino acid-dependent
interactions with the Ragulator complex, which recruits
mTORC1 to the lysosomal membrane during amino acid
sensing (Kim and Kim 2016). Genetic deletion of
structural components of H+-ATPase suppressed amino
acid-induced S6K phosphorylation in Drosophila and
mammalian cells (Zoncu et al. 2011). Functional inhibi-
tion of H+-ATPase activity by chemical inhibitors or by
RNAi abrogated mTOR translocation to lysosomes upon
amino acid stimulation (Zoncu et al. 2011). These results
demonstrate that amino acids activate mTORC1 by stim-
ulating its translocation to the lysosomal membrane
where it forms a super-complex involving the H+-ATPase
(Zoncu et al. 2011), suggesting that H+-ATPase is part of
the amino acid-induced signaling pathway that culminates
in mTORC1 activation (Pena-Llopis et al. 2011).
The reciprocal effect of mTORC1 regulating H+-
ATPase also has been identified because mTORC1 upreg-
ulated the expression of H+-ATPases in immortalized
mouse embryo fibroblast (MEF) cells from Tsc2/ mice
(Pena-Llopis et al. 2011). In addition, mTORC1 facilitates
the assembly of V0 and V1 domains of H+-ATPase. These
results (Sancak et al. 2010; Pena-Llopis and Brugarolas
2011; Pena-Llopis et al. 2011; Zoncu et al. 2011; Kim and
Kim 2016) indicate that TSC gene deletion enhances H+-
ATPase expression via mTORC1, which, requires H+-
ATPase for sustained activity. This amplification loop
may play a significant role in the dysregulation of cell
growth, expansion of A-intercalated cells and cystogenesis
subsequent to initial signals by TSC mutant cells. Interest-
ingly, our results demonstrate that, despite this new dis-
ease mechanism, mTORC1 inhibition can lead to
improvement in the patients suffering from TSC renal
cystic disease.
TSC cystogenesis has some significant differences with
reported pathogenesis in ADPKD, where kidney cysts
may originate from multiple nephron segments but pre-
dominantly arises from the collecting duct (Harris 2002;
Grantham 2015). Fluid accumulation in ADPKD cysts is
caused by active chloride secretion via AVP-stimulated
cAMP-mediated CFTR activation (Sullivan et al. 1998;
de Lemos Barbosa et al. 2016). A prostaglandin E2
(PGE2)-induced chloride secretion mechanism in
collecting duct cells involving cAMP-CFTR- and/or cal-
cium-dependent Cl channel also has been identified
(Rajagopal et al. 2014). Within cysts originating from
collecting duct in ADPKD, both intercalated and princi-
pal cells are present and principal cells play an impor-
tant role in fluid secretion (Sullivan et al. 1998; de
Lemos Barbosa et al. 2016). Contrary to cysts in
ADPKD, our studies using two disparate models
demonstrate that cyst epithelia in adult Tsc1- and Tsc2-
KO mice is almost exclusively comprised of A-interca-
lated cells, with very few or no principal cells. As such,
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intracellular cAMP-activation by AVP may not be a
dominant driving force in cyst fluid accumulation and
expansion in TSC. Furthermore, whereas our studies
clearly demonstrate a uniform and strong expression of
apical PRR in the cyst epithelia in Tsc-2 KO mice, PKD
cysts show a basolateral localization of PRR in principal
cells (Saigusa et al. 2015). The cystic mTORC1-activated
ADPKD cell could still utilize the activation loop
involving the basolateral H+-ATPase, but the cells
involved and H+-ATPase location would be different
than that for the TSC cystogenesis.
The mTORC1 activation may involve the cystoprotein
polycystin-1 (PC-1) in explaining cystogenesis, and may
help explain why the PKD1/TSC2 contiguous gene syn-
drome has such a severe phenotype. mTORC1 activity
negatively regulates the biogenesis of PC-1 and proper
trafficking of the PC-1/2 complex to cilia (Fig. 7B). While
PC-1 is located on the cilia of principal cells, it is also
found on other cell membranes including intercalated
cells (Scheffers et al. 2000; Kim et al. 2014), and is
strongly expressed on extracellular vesicles (Hogan et al.
2009). Genetic interaction studies have revealed that PC-1
downregulation by mTORC1 leads to cystogenesis in Tsc1
mutants (Pema et al. 2016). These findings potentially
explain the severe renal manifestations of the PKD1/TSC2
contiguous gene syndrome. This mechanism also helps
explain the Eker rat model described by the Walker labo-
ratory, that developed severe cystic disease and gave rise
to the cell line EKT2 (Cai et al. 2003). It is intriguing,
given the inputs of von Hippel Lindau protein (Siroky
et al. 2009; Elorza et al. 2012) and folliculin (Hasumi
et al. 2009) proteins into mTORC1 activity, to posit that
these phakomatoses may also arise from a similar mecha-
nism as TSC renal cystic disease.
The disease phenotypic adaption mechanism identified
in our animal models complicates the mechanistic under-
standing of autosomal dominant disease expression. For
autosomal dominant polycystic kidney disease, both
somatic mutation (second hit”) and haploinsufficiency
mechanisms have been put forward. For TSC renal dis-
ease, somatic mutation has been favored and has been
shown for angiomyolipomata (Henske et al. 1995), but
this is not present in the brain tubers or renal cysts
(Henske et al. 1996; Bonsib et al. 2016). Human TSC cys-
tic epithelium continues to express the TSC gene prod-
ucts, hamartin and tuberin (Bonsib et al. 2016). In TSC
renal cystic disease, both loss of heterozygosity in the
inciting cell, and an induced or reprogrammed gain of
function in the genetically normal cyst forming epithe-
lium, is involved. The cystic phenotype may depend on
the presence of A-intercalated cells. The Aqp2CreTsc2
renal medullary collecting duct cells are devoid of cysts
despite their lack of tuberin expression. The cystic disease
may require the intercalated cell plasticity for disease phe-
notype manifestation (Roy et al. 2015). This novel mech-
anism better explains the TSC brain tubers. The
genetically abnormal giant cell could use extracellular
vesicles to reprogram normal cells to participate in the
tuber formation, as supported by detailed genetic analysis
of tubers (Crino et al. 2010). It is intriguing that mutant
pericytes that likely give rise to the TSC-associated renal
angiomyolipoma (Siroky et al. 2014) could also be
involved in TSC renal cystogenesis. Pericytes that have
lost TSC gene function may be responsible for altered
blood brain barrier function giving rise to the tensor
weighted imaging findings in TSC (Jurkiewicz et al. 2007;
Arulrajah et al. 2009; Ertan et al. 2010) and may partici-
pate in inducing subependymal giant cell astrocytoma for-
mation, a TSC tumor also sometimes identified without
loss of heterozygosity (Parry et al. 2000; Bongaarts et al.
2017; Roux et al. 2017), possibly through this extracellu-
lar vesicle mechanism. The expansion of A-intercalated
cell as well as potential role for extracellular vesicles in
many aspects of TSC renal cystic disease manifestation
offers new therapeutic opportunities for intervention in
this disease.
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